Eli Lilly’s Mounjaro shows similar heart health benefits as Trulicity
Hand Lilly On Thursday, the diabetes medication that broke box office records showed that Mounjaro showed heart health benefits in late stage attempt, and that the company directly compared the old diabetes therapy with Trulicity.
Mounjaro met the main goal of showing that the study was not worse than trulitis to treat established people with Type 2 diabetes and cardiovascular disease. Eli Lilly said that the new data believes that Mounjaro has strengthened the case for the first choice of those who recipe for patients with type 2 diabetes. The probability of heart disease or stroke twice like those who do not have disease.
The results also come as Trulity, a best -selling drug for Eli Lilly, and has a patent time in 2027 that can further increase Mounjaro’s position in the diabetes market.
Mounjaro met the main objective of approximately five years of study, which reduced the risk of cardiovascular death, heart attack or stroke by 8% compared to trulite in adults in Type 2 diabetes and built -in cardiovascular disease. It was the longest and largest attempt to have registered to more than 13,000 people about Tirzepathide, the active ingredient in Mounjaro.
The company said Mounjaro showed “more comprehensive” benefits on trulite at the hearing, including 16% lower mortality rate and more kidney protection for any reason. Although Mounjaro’s data was generally promising, he did not meet the criteria of some analysts because Trulity was accepted as “superior”.
Some clinicians assume that Mounjaro can provide cardiovascular benefits, especially the low risk of low cardiovascular events, he said.
However, the difference in the rate of death for any reason between Mounjaro and Trulity is Dr. David Broome said “really pretty deep” and “clinically meaningful for clinicians.”
That data helps measure the difference between Mounjaro and Tulity, which will help providers and patients identify the best treatment to advance in common decision -making processes. Broome said that among patients and providers, those who prescribe them will ultimately depend on various factors such as insurance scope, side effects of a particular drug, and how much the patient has tolerated them.
The Clinical Director of the Center for Prevention of Cardiovascular Disease in Nyu Langone Heart. Howard Weintraub called Mounjaro as the “winner” in trying, just the downward, slightly more side effects than Trulity. However, the results may not motivate more people to start Mounjaro, and the higher the higher list price of the drug may prevent insurance companies from covering it if not significantly better than Trulity.
Weintraub said that when all results were presented at a European medical meeting and published in a refereed magazine in autumn, he expects the data to be too much “digging”.
Eli Lilly saw the trial results as an indication that clinicians should choose Mounjaro for the patient group.
Lilly Cardiometabolic Health President Ken Custer, “strengthens the general story. I think, ‘Why don’t you choose Mounjaro?’ ‘He said.
The results said, “For a patient with 2 diabetes and type 2 diabetes, he doubts that there is a right medication for a cardiovascular risky patient.”
The results come as Eli Lilly strengthens his leadership Novo Nordisk In the market that explodes for weight loss and diabetes medicines. Studies from both companies have shown the additional health benefits of their medication for cases such as obstructive sleep apnea and chronic kidney disease.
Eli Lilly plans to send heart health data to global regulators by the end of the year, and the company said that in 2026, Mounjaro’s approval and expansion insurance for this purpose.
Company Working Currently Cardiovascular benefits of Zepbound in patients with obesity and cardiovascular disease. According to Eli Lilly’s website, the third stage is expected to be completed in 2027.
Regulators may not significantly expand the use of the drug, even if it approves Mounjaro to treat heart disease in patients with type 2 diabetes. This is because Mounjaro’s current approval for Type 2 diabetes already covers most of these patients: 30% of people with type 2 diabetes There is also cardiovascular disease according to the Heart Foundation.
In a research note before the data, TD Cowen analyst Steve Scala said that if the intake of Tyrzptide shows similar heart health benefits with trulity, he believes that he would “not be greatly affected”.
Leerink Partners Analyst David Risinger, in a separate note in June, is already gaining “an important adoption” in the market because of the “strong profile” in the throat. Experts, Tyrzepathide’s cardiovascular benefits are superior, regardless of whether the study of Trulity match, regardless of whether the match, the results of the doctors’ decisions “significantly” said.
Mounjaro showed greater improvements than trulicity when it came to reduce body weight and A1C, a measure of some cardiovascular measurements and blood sugar levels.
Safety data of both Mounjaro and Trulicity were often consistent with the past observed. The most frequently reported adverse events for both drugs are associated with gastrointestinal and often moderately severe.
– Angelica Peebles from CNBC contributed to this report.
